timothy sykes logo

Stock News

Hims & Hers Posts Robust Growth Boosted by New Acquisition

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 2/25/2026, 2:33 pm ET 2/25/2026, 2:33 pm ET | 5 min 5 min read
Hims & Hers Posts Robust Growth Boosted by New Acquisition Thumbnail

Hims & Hers Health Inc. stocks have been trading up by 4.85 percent following promising expansion news in new markets.

Candlestick Chart

Live Update At 14:32:45 EST: On Wednesday, February 25, 2026 Hims & Hers Health Inc. stock [NYSE: HIMS] is trending up by 4.85%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Hims & Hers Health, Inc. closes 2025 with a noteworthy high as revenues rise by 59% to $2.35 billion. This commendable growth comes on the heels of astute strategic planning with net income bumping up positively to $128 million. At the same time, Adjusted EBITDA more than doubles to $318 million, marking a significant operational efficiency improvement.

Capped with a subscriber base inching up by 13% YoY to hit the 2.5 million mark, the enhanced ARPU further elucidates a promising subscriber monetization trend. Heading into 2026, the top-line trajectory anticipates the continuation of such stellar performance, even as operating margins hover flat. Interestingly though, the balance sheet observes a free cash flow dip in 2025, primarily fueled by heavy investments and acquisitions. However, forward-looking guidance pegged for 2026 hints at $2.7 billion to $2.9 billion revenue range, surpassing previous market predictions.

Adding depth to the company’s financial muscles, this escalating growth is underscored by broader international aspirations. More notably, the acquisition of Eucalyptus brings forward an exciting phase, expected to spur global expansion within Australia, UK, Germany, Canada, and Japan. Thus, stitching the road map to harness a richer telehealth and consumer health platform worldwide. By targeting $6.5 billion revenue and $1.3 billion in Adjusted EBITDA by 2030, the company paints an ambitious yet achievable blueprint into the coming decade.

Market Reactions

The news about the acquisition sends positive ripples in the stock market, nudging Hims & Hers shares up by 2.8% pre-market. This uptick signifies a robust investor confidence born out of the strategic acquisition, which aligns with the company’s long-term growth story. Another layer of positive reception is the brighter financial outlook for fiscal year 2026 which comfortably beats market expectations, precisely promising stronger profitability margins and a visible path to consistent returns.

Although targeted international expansion swerves off into a promising diversification for Hims & Hers, market players persistently weigh the prospects and challenges inherent in the integration process with Eucalyptus. If navigated seamlessly, such integration would further bolster earnings and revenue streams across strategic geographical regions.

Intriguingly, following the weak spillover of Barclays reducing the price target while maintaining an Overweight rating, TD Cowen’s decision to lower it further provides a dual narrative. On one hand, it speaks to more moderate immediate upside, but on the other, it attests to cautious optimism around the company’s fundamental robustness and potential impediments related to regulatory landscapes.

More Breaking News

Conclusion

In sum, the surge in financial health championed by Hims & Hers aligns tidily with its recent strategic maneuvers and quest for sustainable growth. While immediate challenges whirl around trading and acquisitions, they seem overshadowed by the longer-term gains of strategic scaling and geographical diversification. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” By utilizing Eucalyptus’ prowess, Hims & Hers bulldozes a path toward becoming an influential global household pillar within the virtual health spectrum, thus, maintaining its position as a formidable player in the healthcare sector. Market sentiment seems to tread on firm ground, with eager speculation pinning on favorable horizons. If fiscal discipline coincides with aggressive yet calculated growth tactics, 2026 stands as the threshold year to unlock a cascade of future success stories for Hims & Hers.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”